Chemotherapy accelerates immune-senescence and functional impairments of Vδ2pos T cells in elderly patients affected by liver metastatic colorectal cancer

Table 1 Neoadjuvant combination chemotherapy (CHT) with or without biological therapy (BT) of enrolled CLM patients

	Patients (number)	Patients (%)	CHT cycles (mean number ± SD)
CHT/BT Regimens^a	58	82	8.7 ± 5.3
Combination Therapy with Biologicals
FOLFOX + VEGF-A mAb	12	21.5	7.7 ± 1.4
FOLFIRI + EGFR mAb	11	19.0	11.7 ± 4.3
FOLFIRI + VEGF-A mAb	10	17.2	7.5 ± 3.3
FOLFIRI + FOLFOX + VEGF-A mAb	7	12.0	13.0 ± 3.2
FOLFOX + EGFR mAb	6	10.3	11.0 ± 2.3
XELOX + VEGF-A mAb	4	6.9	8.5 ± 3.4
Combination Therapy without Biologicals
FOLFOX	4	6.9	5.0 ± 1.6
XELOX	2	3.4	4.6 ± 1.2
FOLFIRI	2	3.4	7.0 ± 6.0
Naïve for CHT	13	18	0.0
Total Patients	71

FOLFOX: 5-fluorouracil/oxaliplatin; XELOX: capecitabine/oxaliplatin; FOLFIRI: 5-fluorouracil/irinotecan
EGFR mAb Epidermal Growth Factor Receptor inhibitor monoclonal antibody
VEGF-A mAb Vascular Endothelial Growth Factor A monoclonal antibody
^aNote:
a) All CLM patients completed their last CHT cycle at least 6 weeks before the blood draws used for our experiments and before surgical procedures
b) The table refers all therapies received by CLM patients before surgery
c) More than 91% of all CLM patients received one line therapy and all other patients received two lines (1^st and 2^nd) combination therapy: 3 patients received 1^st FOLFOX and 2^nd FOLFIRI + VEGF-A; 1 patient received 1^st FOLFIRI + VEGF-A and 2^nd FOLFOX + VEGF-A, and 1 patient received 1^st FOLFIRI + VEGF-A and 2^nd FOLFOX